G-CSF and GM-CSF in Neutropenia

Overview

Journal J Immunol

Specialty Allergy & Immunology

Date 2015 Aug 9

PMID 26254266

Citations 161

Authors

Hrishikesh M Mehta

Michael Malandra

Seth J Corey

Affiliations

Soon will be listed here.

Abstract

G-CSF and GM-CSF are used widely to promote the production of granulocytes or APCs. The U.S. Food and Drug Administration approved G-CSF (filgrastim) for the treatment of congenital and acquired neutropenias and for mobilization of peripheral hematopoietic progenitor cells for stem cell transplantation. A polyethylene glycol-modified form of G-CSF is approved for the treatment of neutropenias. Clinically significant neutropenia, rendering an individual immunocompromised, occurs when their number is <1500/μl. Current guidelines recommend their use when the risk for febrile neutropenia is >20%. GM-CSF (sargramostim) is approved for neutropenia associated with stem cell transplantation. Because of its promotion of APC function, GM-CSF is being evaluated as an immunostimulatory adjuvant in a number of clinical trials. More than 20 million persons have benefited worldwide, and >$5 billion in sales occur annually in the United States.

Citing Articles

Antifungal immunity: advances in PRR recognition, adaptive responses, and immune-based therapies.

Zhou J, Lu X, He R, Du Y, Zeng B, Feng L Sci China Life Sci. 2025; .

PMID: 40055278 DOI: 10.1007/s11427-024-2835-y.

Secondary Neutropenias.

Ward A Biomedicines. 2025; 13(2).

PMID: 40002910 PMC: 11853056. DOI: 10.3390/biomedicines13020497.

The effect of GM-CSF and predictors of treatment outcome in pediatric septic shock patients.

Yu Z, Tian G, Wang Y, Liu T, Shi P, Ying J Ital J Pediatr. 2025; 51(1):25.

PMID: 39901277 PMC: 11792208. DOI: 10.1186/s13052-025-01863-6.

PSCA-targeted BPX-601 CAR T cells with pharmacological activation by rimiducid in metastatic pancreatic and prostate cancer: a phase 1 dose escalation trial.

Stein M, Dumbrava E, Teply B, Gergis U, Guiterrez M, Reshef R Nat Commun. 2024; 15(1):10743.

PMID: 39737899 PMC: 11685978. DOI: 10.1038/s41467-024-53220-6.

Let It Grow: The Role of Growth Factors in Managing Chemotherapy-Induced Cytopenia.

Alyamany R, Alnughmush A, Alzahrani H, Alfayez M Curr Oncol. 2024; 31(12):8094-8109.

PMID: 39727719 PMC: 11675056. DOI: 10.3390/curroncol31120596.

References

Gerhartz H, Engelhard M, Meusers P, Brittinger G, Wilmanns W, Schlimok G . Randomized, double-blind, placebo-controlled, phase III study of recombinant human granulocyte-macrophage colony-stimulating factor as adjunct to induction treatment of high-grade malignant non-Hodgkin's lymphomas. Blood. 1993; 82(8):2329-39. View

Garber B, Albores J, Wang T, Neville T . A plasmapheresis protocol for refractory pulmonary alveolar proteinosis. Lung. 2015; 193(2):209-11. DOI: 10.1007/s00408-014-9678-2. View

Martins A, Han J, Kim S . The multifaceted effects of granulocyte colony-stimulating factor in immunomodulation and potential roles in intestinal immune homeostasis. IUBMB Life. 2010; 62(8):611-7. PMC: 2916186. DOI: 10.1002/iub.361. View

Paul M, Ram R, Kugler E, Farbman L, Peck A, Leibovici L . Subcutaneous versus intravenous granulocyte colony stimulating factor for the treatment of neutropenia in hospitalized hemato-oncological patients: randomized controlled trial. Am J Hematol. 2013; 89(3):243-8. DOI: 10.1002/ajh.23622. View

Sinha S, Zhu Q, Romero G, Corey S . Deletional mutation of the external domain of the human granulocyte colony-stimulating factor receptor in a patient with severe chronic neutropenia refractory to granulocyte colony-stimulating factor. J Pediatr Hematol Oncol. 2003; 25(10):791-6. DOI: 10.1097/00043426-200310000-00010. View

Carulli G . Effects of recombinant human granulocyte colony-stimulating factor administration on neutrophil phenotype and functions. Haematologica. 1998; 82(5):606-16. View

Theilgaard-Monch K, Jacobsen L, Borup R, Rasmussen T, Bjerregaard M, Nielsen F . The transcriptional program of terminal granulocytic differentiation. Blood. 2004; 105(4):1785-96. DOI: 10.1182/blood-2004-08-3346. View

Dong F, Brynes R, Tidow N, Welte K, Lowenberg B, Touw I . Mutations in the gene for the granulocyte colony-stimulating-factor receptor in patients with acute myeloid leukemia preceded by severe congenital neutropenia. N Engl J Med. 1995; 333(8):487-93. DOI: 10.1056/NEJM199508243330804. View

Egea L, McAllister C, Lakhdari O, Minev I, Shenouda S, Kagnoff M . GM-CSF produced by nonhematopoietic cells is required for early epithelial cell proliferation and repair of injured colonic mucosa. J Immunol. 2013; 190(4):1702-13. PMC: 3563922. DOI: 10.4049/jimmunol.1202368. View

10.

Jeng M, Naidu P, Rieman M, Rodriguez-Galindo C, Nottage K, Thornton D . Granulocyte-macrophage colony stimulating factor and immunosuppression in the treatment of pediatric acquired severe aplastic anemia. Pediatr Blood Cancer. 2004; 45(2):170-5. DOI: 10.1002/pbc.20278. View

11.

Sun D, Andayani T, Altyar A, MacDonald K, Abraham I . Potential cost savings from chemotherapy-induced febrile neutropenia with biosimilar filgrastim and expanded access to targeted antineoplastic treatment across the European Union G5 countries: a simulation study. Clin Ther. 2015; 37(4):842-57. DOI: 10.1016/j.clinthera.2015.01.011. View

12.

Pfreundschuh M, Trumper L, Kloess M, Schmits R, Feller A, Rube C . Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL. Blood. 2004; 104(3):634-41. DOI: 10.1182/blood-2003-06-2095. View

13.

Pitrak D . Effects of granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor on the bactericidal functions of neutrophils. Curr Opin Hematol. 1997; 4(3):183-90. DOI: 10.1097/00062752-199704030-00005. View

14.

Rowe J, Andersen J, Mazza J, Bennett J, Paietta E, Hayes F . A randomized placebo-controlled phase III study of granulocyte-macrophage colony-stimulating factor in adult patients (> 55 to 70 years of age) with acute myelogenous leukemia: a study of the Eastern Cooperative Oncology Group (E1490). Blood. 1995; 86(2):457-62. View

15.

Jack G, Zhang L, Friedman A . M-CSF elevates c-Fos and phospho-C/EBPalpha(S21) via ERK whereas G-CSF stimulates SHP2 phosphorylation in marrow progenitors to contribute to myeloid lineage specification. Blood. 2009; 114(10):2172-80. PMC: 2744575. DOI: 10.1182/blood-2008-11-191536. View

16.

Rosenberg P, Alter B, Bolyard A, Bonilla M, Boxer L, Cham B . The incidence of leukemia and mortality from sepsis in patients with severe congenital neutropenia receiving long-term G-CSF therapy. Blood. 2006; 107(12):4628-35. PMC: 1895804. DOI: 10.1182/blood-2005-11-4370. View

17.

Tazawa R, Trapnell B, Inoue Y, Arai T, Takada T, Nasuhara Y . Inhaled granulocyte/macrophage-colony stimulating factor as therapy for pulmonary alveolar proteinosis. Am J Respir Crit Care Med. 2010; 181(12):1345-54. PMC: 2894410. DOI: 10.1164/rccm.200906-0978OC. View

18.

Smith T, Khatcheressian J, Lyman G, Ozer H, Armitage J, Balducci L . 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol. 2006; 24(19):3187-205. DOI: 10.1200/JCO.2006.06.4451. View

19.

Norton L, Simon R, Brereton H, BOGDEN A . Predicting the course of Gompertzian growth. Nature. 1976; 264(5586):542-5. DOI: 10.1038/264542a0. View

20.

Doulatov S, Notta F, Laurenti E, Dick J . Hematopoiesis: a human perspective. Cell Stem Cell. 2012; 10(2):120-36. DOI: 10.1016/j.stem.2012.01.006. View